The effects of practice on the cognitive test performance 
of neurologically normal individuals assessed at brief 
test–retest intervals

Collie, Alex; Maruff, Paul; Darby, David; McStephen, Michael

doi:10.1017/s1355617703930074

Cited by 373 publications

(300 citation statements)

References 19 publications

Supporting

Mentioning

270

Contrasting

Unclassified

Order By: Relevance

“…For example, the study by Shiroma et al (2014) found that impaired attention, but not impaired processing speed per se, was associated with improved antidepressant response to ketamine. This discrepancy could be, in part, due to the differences in neurocognitive assessments utilized (the MCCB was utilized in the current study, compared with the CogState battery (Collie et al, 2003) in the study by Shiroma et al (2014)). The current study examined neurocognitive function using a comprehensive battery, but optimal biomarker assessments will likely require multi-modal data acquisition, potentially including neuroimaging (Zarate et al, 2013), quantitative electroencephalography (qEEG) (Cook et al, 2013), and peripheral blood markers (Uddin, 2014).…”

Section: Discussionmentioning

confidence: 88%

Neurocognitive Effects of Ketamine and Association with Antidepressant Response in Individuals with Treatment-Resistant Depression: A Randomized Controlled Trial

Murrough

Burdick

Levitch

et al. 2014

Neuropsychopharmacol

115

View full text Add to dashboard Cite

The glutamate N-methyl-D-aspartate (NMDA) receptor antagonist ketamine displays rapid antidepressant effects in patients with treatment-resistant depression (TRD); however, the potential for adverse neurocognitive effects in this population has not received adequate study. The current study was designed to investigate the delayed neurocognitive impact of ketamine in TRD and examine baseline antidepressant response predictors in the context of a randomized controlled trial. In the current study, 62 patients (mean age ¼ 46.2 ± 12.2) with TRD free of concomitant antidepressant medication underwent neurocognitive assessments using components of the MATRICS Consensus Cognitive Battery (MCCB) before and after a single intravenous infusion of ketamine (0.5 mg/kg) or midazolam (0.045 mg/kg). Participants were randomized to ketamine or midazolam in a 2:1 fashion under double-blind conditions and underwent depression symptom assessments at 24, 48, 72 h, and 7 days post treatment using the Montgomery-Asberg Depression Rating Scale (MADRS). Post-treatment neurocognitive assessment was conducted once at 7 days. Neurocognitive performance improved following the treatment regardless of treatment condition. There was no differential effect of treatment on neurocognitive performance and no association with antidepressant response. Slower processing speed at baseline uniquely predicted greater improvement in depression at 24 h following ketamine (t ¼ 2.3, p ¼ 0.027), while controlling for age, depression severity, and performance on other neurocognitive domains. In the current study, we found that ketamine was devoid of adverse neurocognitive effects at 7 days post treatment and that slower baseline processing speed was associated with greater antidepressant response. Future studies are required to further define the neurocognitive profile of ketamine in clinical samples and to identify clinically useful response moderators.

show abstract

Section: Discussionmentioning

confidence: 88%

Neurocognitive Effects of Ketamine and Association with Antidepressant Response in Individuals with Treatment-Resistant Depression: A Randomized Controlled Trial

Murrough

Burdick

Levitch

et al. 2014

Neuropsychopharmacol

115

View full text Add to dashboard Cite

show abstract

“…33,34 At least several of the tests used in our battery (i.e., Trail's test, Finger Tapping test, Digit Span forward, Reaction time) have been reported to lack significant practice effects. 35 To minimize potential practice effects in the current study, tests with alternate forms were selected whenever possible (e.g., 4 forms of the Selective reminding test) and the tests were administered in a predetermined order.…”

Section: Discussionmentioning

confidence: 99%

Cognitive function does not worsen during pegylated interferon and ribavirin retreatment of chronic hepatitis C

et al. 2007

View full text Add to dashboard Cite

Treatment of chronic hepatitis C with pegylated interferon (peginterferon) and ribavirin can cause or exacerbate depression but its effects on cognitive function are largely unknown. The aim of this study was to determine whether treatment with peginterferon and ribavirin adversely impacts cognitive function in patients with chronic hepatitis C. Prior nonresponders to interferon were retreated with peginterferon alfa-2a and ribavirin for 24 (n ‫؍‬ 177) or 48 weeks (n ‫؍‬ 57) in the Hepatitis C Antiviral Long-term Treatment Against Cirrhosis trial. Cognitive function was prospectively assessed using a battery of 10 standardized neuropsychological tests at weeks 0, 24, 48, and 72. Cognitive impairment was defined based upon a global deficit score. The Beck Depression Inventory and Brief Symptom Inventory were used to assess mood status. The 57 subjects who completed 48 weeks of antiviral therapy reported significant increases in difficulty concentrating, emotional distress, and symptoms of depression, all of which improved after cessation of therapy [P < 0.0001, analysis of variance (ANOVA)]. Nonetheless, the frequency of cognitive impairment did not increase during the first 24 weeks of treatment in 177 patients (34% versus 32%, P ‫؍‬ 0.64) nor in the 57 patients completing 48 weeks of treatment (P ‫؍‬ 0.48, ANOVA). Conclusion: Retreatment of prior non-responders with peginterferon and ribavirin was not associated with objective evidence of cognitive impairment as measured by a comprehensive battery of neuropsychological tests. The lack of cognitive impairment is reassuring and suggests that self-reported symptoms of cognitive dysfunction are more likely related to the systemic and psychiatric side effects of antiviral treatment rather than measurable changes in cognition.

show abstract

“…All participants (training group and control group) were tested twice, before the intervention group received the intervention. This 'dual baseline procedure' was used in order to reduce practice and procedure-learning effects [37]. The mean interval between measurements 1 and 2 was 17 days (S.D.…”

Section: Methodsmentioning

confidence: 99%

Effect of a structured course involving goal management training in older adults: A randomised controlled trial

Hooren

Valentijn

Bosma

et al. 2007

Patient Education and Counseling

View full text Add to dashboard Cite

Objective-The objective of this study was to investigate the effects of a structured 6-week neuropsychological course on the executive functioning of older adults with cognitive complaints.Methods-A randomised controlled design was used involving 69 community dwelling individuals aged 55 years and older. Both objective and subjective measures were included to assess executive functioning. General linear model with repeated measures analysis of variance was used to examine the intervention effects.Results-After the intervention, the participants in the intervention group were significantly less annoyed by their cognitive failures, were better able to manage their executive failures and reported less anxiety symptoms than those in the waiting list control group.Conclusion-These findings indicate that a combination of psycho-education and training has the potential to change the attitude of older individuals towards their cognitive functioning.Practice implications-Because this training focussed on cognitive functions that are among the first to decline in older adults and the subjective evaluation of the people after training was quite favourable, the proposed intervention may be considered a valuable contribution to cognitive interventions for older adults.

show abstract

The effects of practice on the cognitive test performance of neurologically normal individuals assessed at brief test–retest intervals

Cited by 373 publications

References 19 publications

Neurocognitive Effects of Ketamine and Association with Antidepressant Response in Individuals with Treatment-Resistant Depression: A Randomized Controlled Trial

Neurocognitive Effects of Ketamine and Association with Antidepressant Response in Individuals with Treatment-Resistant Depression: A Randomized Controlled Trial

Cognitive function does not worsen during pegylated interferon and ribavirin retreatment of chronic hepatitis C

Effect of a structured course involving goal management training in older adults: A randomised controlled trial

Contact Info

Product

Resources

About